D-0484-2019 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0484-2019 was initiated by Lupin Pharmaceuticals Inc. on Feb 1, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification test results in related substance at three-month long term stability study was obtained. The recall status is terminated (terminated Jun 26, 2020). Affected quantity: 43,860 3ml bottles.

Recall details

Product Type
Drugs
Report Date
Feb 20, 2019
Initiation Date
Feb 1, 2019
Termination Date
Jun 26, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
43,860 3ml bottles

Product description

Moxifloxacin Ophthalmic Solution USP, 0.5%, 3 mL dropper bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 Manufactured by: lupin Limited Pithampur (M.P.) 454 775 India. NDC 68180-422-01

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification test results in related substance at three-month long term stability study was obtained.

Distribution pattern

Product was distributed by 5 wholesalers, 6 drug chains, 4 mail order pharmacies and 1 mail order pharmacy/supermarket who may have further distribute the product throughout the United States.

Code information

Lot Numbers: H705562, H705563, EXP. 11/2019; H800616, EXP. 01/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0484-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0484-2019. Report a data issue: hello@regdatalab.com.